HU228862B1 - The use of an ingenane compound for production medicament useful for treatment cancer - Google Patents
The use of an ingenane compound for production medicament useful for treatment cancer Download PDFInfo
- Publication number
- HU228862B1 HU228862B1 HU0004262A HUP0004262A HU228862B1 HU 228862 B1 HU228862 B1 HU 228862B1 HU 0004262 A HU0004262 A HU 0004262A HU P0004262 A HUP0004262 A HU P0004262A HU 228862 B1 HU228862 B1 HU 228862B1
- Authority
- HU
- Hungary
- Prior art keywords
- cells
- cell
- compound
- treatment
- cancer
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims description 37
- 206010028980 Neoplasm Diseases 0.000 title claims description 21
- 201000011510 cancer Diseases 0.000 title claims description 13
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000003814 drug Substances 0.000 title claims description 3
- -1 ingenane compound Chemical class 0.000 title 1
- 210000004027 cell Anatomy 0.000 claims description 117
- 230000000694 effects Effects 0.000 claims description 36
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 10
- 201000001441 melanoma Diseases 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 230000001413 cellular effect Effects 0.000 claims description 6
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 230000035755 proliferation Effects 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 210000001072 colon Anatomy 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 201000000849 skin cancer Diseases 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 235000014121 butter Nutrition 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
- 239000000284 extract Substances 0.000 description 18
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 18
- 238000010790 dilution Methods 0.000 description 16
- 239000012895 dilution Substances 0.000 description 16
- 244000269722 Thea sinensis Species 0.000 description 13
- 235000013616 tea Nutrition 0.000 description 13
- 239000000126 substance Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 241000196324 Embryophyta Species 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 235000002639 sodium chloride Nutrition 0.000 description 7
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000004611 spectroscopical analysis Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000469 ethanolic extract Substances 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 108700008625 Reporter Genes Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000009621 actinic keratosis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 239000000287 crude extract Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000012894 fetal calf serum Substances 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 206010016531 fetishism Diseases 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000004575 stone Substances 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 239000003104 tissue culture media Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 2
- 235000014966 Eragrostis abyssinica Nutrition 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010057281 Lipocalin 1 Proteins 0.000 description 2
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 240000003768 Solanum lycopersicum Species 0.000 description 2
- 206010047924 Wheezing Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 210000003918 fraction a Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241001103870 Adia Species 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 244000294263 Arctium minus Species 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000147222 Astroboa Species 0.000 description 1
- HNNIWKQLJSNAEQ-UHFFFAOYSA-N Benzydamine hydrochloride Chemical compound Cl.C12=CC=CC=C2C(OCCCN(C)C)=NN1CC1=CC=CC=C1 HNNIWKQLJSNAEQ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000005156 Brassica carinata Nutrition 0.000 description 1
- 244000257790 Brassica carinata Species 0.000 description 1
- 101100503774 Caenorhabditis elegans gbb-1 gene Proteins 0.000 description 1
- 101100309447 Caenorhabditis elegans sad-1 gene Proteins 0.000 description 1
- 235000006810 Caesalpinia ciliata Nutrition 0.000 description 1
- 241000059739 Caesalpinia ciliata Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 238000011346 DNA-damaging therapy Methods 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000500884 Ephemera Species 0.000 description 1
- 244000140063 Eragrostis abyssinica Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 244000060234 Gmelina philippensis Species 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 101150030817 HPT1 gene Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 241000221089 Jatropha Species 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 240000000599 Lentinula edodes Species 0.000 description 1
- 235000001715 Lentinula edodes Nutrition 0.000 description 1
- 241000985284 Leuciscus idus Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150087188 Mast1 gene Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000549343 Myadestes Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101100462124 Oryza sativa subsp. japonica AHP1 gene Proteins 0.000 description 1
- 235000008098 Oxalis acetosella Nutrition 0.000 description 1
- 240000007930 Oxalis acetosella Species 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241000269800 Percidae Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 235000014258 Polygonum bistorta Nutrition 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101100422342 Salmonella typhimurium (strain LT2 / SGSC1412 / ATCC 700720) ssaM gene Proteins 0.000 description 1
- 206010039740 Screaming Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000288726 Soricidae Species 0.000 description 1
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 1
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 240000002871 Tectona grandis Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 241000469816 Varus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 239000012445 acidic reagent Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000010307 cell transformation Effects 0.000 description 1
- 230000003822 cell turnover Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000005100 correlation spectroscopy Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000013367 dietary fats Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012581 double quantum filtered COSY Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- ARNAHNTWKSJFHG-KVVVOXFISA-N ethanamine;(z)-octadec-9-enoic acid Chemical compound CCN.CCCCCCCC\C=C/CCCCCCCC(O)=O ARNAHNTWKSJFHG-KVVVOXFISA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000010520 ghee Substances 0.000 description 1
- 230000002710 gonadal effect Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000000238 one-dimensional nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 210000004417 patella Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000016914 ras Proteins Human genes 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 102220152492 rs146391348 Human genes 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 229910052572 stoneware Inorganic materials 0.000 description 1
- ZEGFMFQPWDMMEP-UHFFFAOYSA-N strontium;sulfide Chemical compound [S-2].[Sr+2] ZEGFMFQPWDMMEP-UHFFFAOYSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011269 tar Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 1
- 229960001254 vildagliptin Drugs 0.000 description 1
- 235000015041 whisky Nutrition 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HUS1300063 HUS1300063I1 (hu) | 1997-08-19 | 2013-10-30 | Egy ingenán vegyület alkalmazása rák kezelésére alkalmas gyógyszerkészítmény elõállítására |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO8640A AUPO864097A0 (en) | 1997-08-19 | 1997-08-19 | Anti-cancer compounds |
| PCT/AU1998/000656 WO1999008994A1 (en) | 1997-08-19 | 1998-08-19 | Anti-cancer compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0004262A1 HUP0004262A1 (hu) | 2001-08-28 |
| HU228862B1 true HU228862B1 (en) | 2013-06-28 |
Family
ID=3802927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0004262A HU228862B1 (en) | 1997-08-19 | 1998-08-19 | The use of an ingenane compound for production medicament useful for treatment cancer |
| HUS1300063 HUS1300063I1 (hu) | 1997-08-19 | 2013-10-30 | Egy ingenán vegyület alkalmazása rák kezelésére alkalmas gyógyszerkészítmény elõállítására |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUS1300063 HUS1300063I1 (hu) | 1997-08-19 | 2013-10-30 | Egy ingenán vegyület alkalmazása rák kezelésére alkalmas gyógyszerkészítmény elõállítására |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US6432452B1 (https=) |
| EP (1) | EP1015413B1 (https=) |
| JP (3) | JP2001515059A (https=) |
| CN (1) | CN1266421B (https=) |
| AT (1) | ATE397580T1 (https=) |
| AU (1) | AUPO864097A0 (https=) |
| BE (1) | BE2013C026I2 (https=) |
| BR (1) | BR9811327A (https=) |
| CA (1) | CA2301082C (https=) |
| CY (2) | CY1108303T1 (https=) |
| DE (1) | DE69839586D1 (https=) |
| DK (1) | DK1015413T3 (https=) |
| ES (1) | ES2308810T3 (https=) |
| HU (2) | HU228862B1 (https=) |
| LU (1) | LU92185I2 (https=) |
| PT (1) | PT1015413E (https=) |
| WO (1) | WO1999008994A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO864097A0 (en) * | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
| US6822267B1 (en) * | 1997-08-20 | 2004-11-23 | Advantest Corporation | Signal transmission circuit, CMOS semiconductor device, and circuit board |
| US7078434B1 (en) * | 1999-08-12 | 2006-07-18 | Societe De Conseils De Recherches Et D'applications Scientifiques Sas | Use of Ginkgo extract |
| AUPQ801700A0 (en) * | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
| AU748542B2 (en) * | 2000-06-07 | 2002-06-06 | Leo Laboratories Limited | Therapeutic agents - III |
| AUPQ923100A0 (en) * | 2000-08-07 | 2000-08-31 | Peplin Research Pty Ltd | Treatment of prostate cancer |
| US6923993B2 (en) * | 2001-12-12 | 2005-08-02 | Nicholas J. Donato | Process of isolating extract from the Euphorbia obesa plant and methods for using the same |
| MY139563A (en) | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| US7154002B1 (en) | 2002-10-08 | 2006-12-26 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7250514B1 (en) | 2002-10-21 | 2007-07-31 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US7381825B2 (en) | 2003-03-17 | 2008-06-03 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| DE602004026897D1 (de) | 2003-10-14 | 2010-06-10 | Baxter Healthcare Sa | Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate |
| US20050137234A1 (en) * | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| CA2556550A1 (en) * | 2004-02-17 | 2005-09-01 | University Of South Florida | Cytotoxin compound and method of isolation |
| AU2005218759B2 (en) * | 2004-02-27 | 2009-07-16 | Antisense Pharma Gmbh | Pharmaceutical composition |
| DE102004044428A1 (de) * | 2004-09-14 | 2006-03-30 | Toximed Gmbh | Verfahren und pharmazeutischer Wirkstoff zur Bekämpfung von Plasmodien |
| CA2589992C (en) * | 2004-12-13 | 2014-04-22 | Peplin Research Pty Ltd | Treatment of solid cancers |
| AU2005316185B2 (en) * | 2004-12-13 | 2012-04-12 | Leo Laboratories Limited | Treatment of solid cancers |
| EP1824831A2 (en) | 2004-12-16 | 2007-08-29 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1896436A2 (en) | 2005-05-11 | 2008-03-12 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| US20090035403A2 (en) * | 2005-06-16 | 2009-02-05 | Mmi Corporation | Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof |
| US7655620B2 (en) * | 2005-07-07 | 2010-02-02 | Cancure Laboratories, Llc | Use of one or more metal carriers to selectively kill mammalian cells |
| EA200800321A1 (ru) * | 2005-07-14 | 2008-06-30 | Такеда Сан Диего, Инк. | Ингибиторы гистондеацетилазы |
| US9597311B2 (en) * | 2005-09-27 | 2017-03-21 | Robert Benson Aylor | Suppression and prevention of tumors |
| KR20080077625A (ko) | 2005-11-25 | 2008-08-25 | 페플린 리서치 피티이 리미티드 | 상처 치유 방법 |
| WO2007065925A2 (de) * | 2005-12-07 | 2007-06-14 | Toximed Gmbh | Zusammensetzung zur behandlung von melanomen und hautunreinheiten sowie kosmetisches hautpflegemittel |
| GB0525680D0 (en) | 2005-12-16 | 2006-01-25 | Peplin Ltd | Therapeutic compositions |
| JP2009525955A (ja) * | 2006-01-13 | 2009-07-16 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| US20080069809A1 (en) * | 2006-04-20 | 2008-03-20 | Ogbourne Steven M | Compositions and methods for the diagnosis and treatment of cancer |
| US20080207738A1 (en) * | 2007-02-28 | 2008-08-28 | Cancure Laboratories, Llc | Drug combinations to treat drug resistant tumors |
| TWI389699B (zh) * | 2009-02-13 | 2013-03-21 | 高雄醫學大學 | 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法 |
| EP2395993B1 (en) * | 2009-02-13 | 2017-06-21 | Leo Laboratories Limited | Skin treatment |
| SMT201700350T1 (it) | 2010-04-16 | 2017-09-07 | Leo Pharma As | Mebutato di ingenolo cristallino ortorombico |
| RS58784B1 (sr) * | 2010-05-06 | 2019-06-28 | Milosavljevic Goran | Farmaceutske kompozicije niske toksičnosti koje sadrže diterpenska jedinjenja sa antineoplastičnim dejstvom |
| WO2012061086A2 (en) * | 2010-10-25 | 2012-05-10 | Niiki Pharma Inc. | Method of treating neuroendocrine tumors |
| WO2012080466A2 (en) | 2010-12-17 | 2012-06-21 | Leo Pharma A/S | Ingenols for treating seborrheic keratosis |
| CA2822360A1 (en) | 2010-12-22 | 2012-06-28 | Leo Laboratories Limited | Ingenol-3-acylates i |
| CA2822312A1 (en) | 2010-12-22 | 2012-06-28 | Gunnar Grue-Sorensen | 3-acyl-ingenols ii |
| JP5845283B2 (ja) | 2010-12-22 | 2016-01-20 | レオ・ラボラトリーズ・リミテッドＬｅｏ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ | インゲノール−３−アシラートｉｉｉおよびインゲノール−３−カルバメート |
| US8858953B2 (en) | 2011-05-09 | 2014-10-14 | Yu-Hwa Peter Sheng | Herbal composition for treating cancer |
| WO2012176015A1 (en) | 2011-06-24 | 2012-12-27 | Leo Pharma A/S | Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate |
| KR101374760B1 (ko) * | 2011-10-26 | 2014-03-17 | 한국생명공학연구원 | 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물 |
| AU2013283511B2 (en) | 2012-06-26 | 2017-10-26 | Leo Laboratories Limited | 3-O-heteroaryl-ingenol |
| CN103655674A (zh) * | 2012-09-11 | 2014-03-26 | 清华大学深圳研究生院 | 乳浆大戟提取物及其制备方法和应用 |
| KR101578404B1 (ko) | 2014-03-18 | 2015-12-18 | 원광대학교 산학협력단 | 대극속 식물 추출물 또는 분획물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물 |
| US9948261B2 (en) * | 2014-11-20 | 2018-04-17 | Tymphany Hk Limited | Method and apparatus to equalize acoustic response of a speaker system using multi-rate FIR and all-pass IIR filters |
| CN106905950A (zh) * | 2015-10-01 | 2017-06-30 | 钱秀英 | 一种用于判断时间的生物显色剂 |
| CN105255476B (zh) * | 2015-10-01 | 2017-10-13 | 申俊 | 基于生物显色技术以服务于物联网的储物箱 |
| US12502369B2 (en) | 2015-11-11 | 2025-12-23 | K-Gen, Inc. | Methods of cancer treatment |
| US9758786B2 (en) | 2016-02-09 | 2017-09-12 | Autotelic, Llc | Compositions and methods for treating pancreatic cancer |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| MY197240A (en) | 2016-09-02 | 2023-06-07 | Thailand Center Of Excellence For Life Sciences | Method for preparing an extract of hevea latex and composition thereof |
| CN110663685B (zh) * | 2019-10-23 | 2021-10-12 | 扬州大学 | 一种介孔二氧化硅负载ppte的纳米农药制剂 |
| CN112441924B (zh) * | 2020-12-11 | 2024-05-03 | 浙江工业大学 | 巨大戟二萜化合物及其提取方法与应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2902506A1 (de) * | 1979-01-23 | 1980-07-24 | Deutsches Krebsforsch | Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel |
| JPS5813571A (ja) * | 1981-07-14 | 1983-01-26 | Sagami Chem Res Center | ジヒドロフラン誘導体及びその製造方法 |
| US4418064A (en) | 1982-09-29 | 1983-11-29 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone |
| US4560774A (en) | 1982-11-17 | 1985-12-24 | Arizona State University | Macrocyclic lactones |
| US5716968A (en) | 1986-06-11 | 1998-02-10 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. H. |
| US5886017A (en) | 1986-06-11 | 1999-03-23 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. E. |
| US5886019A (en) | 1986-06-11 | 1999-03-23 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. F. |
| US5145842A (en) | 1986-06-11 | 1992-09-08 | Alder Research Center Limited Partnership | Protein kinase c. modulators. d. |
| US5750568A (en) | 1986-06-11 | 1998-05-12 | Procyon Pharmaceuticals, Inc. | Protein kinase C Modulators. L. |
| US5891870A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators Q |
| US5643948A (en) | 1986-06-11 | 1997-07-01 | Procyon Pharmaceuticals, Inc. | Protein kinase C modulators. K. |
| IL82811A0 (en) | 1986-06-11 | 1987-12-20 | Alder Res Center Corp | Anti-inflammatory compositions containing methanol derivatives and novel compounds contained therein |
| US5891906A (en) | 1986-06-11 | 1999-04-06 | Procyon Pharmaceuticals, Inc. | Polyacetate-derived phorboids having anti-inflammatory and other uses |
| DE3805965A1 (de) * | 1988-02-25 | 1989-09-07 | Tamas Geb Szenasi Eszter | Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe |
| DE4102054A1 (de) | 1991-01-24 | 1992-07-30 | Geb Szenasi Tamas | Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe |
| CN1047084C (zh) * | 1993-03-30 | 1999-12-08 | 刘振宪 | 人参口服液及其制造方法 |
| US6593371B1 (en) * | 1993-05-19 | 2003-07-15 | Jeff J. Staggs | Treatment for wart and related disorders |
| CN1048164C (zh) * | 1993-08-24 | 2000-01-12 | 吴雪姣 | 复方菝葜口服液 |
| JP2913451B2 (ja) | 1994-06-22 | 1999-06-28 | 株式会社イナックス | 防水パンの高さ調整構造 |
| JPH08245505A (ja) | 1994-09-09 | 1996-09-24 | Tosoh Corp | ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤 |
| JPH08176002A (ja) | 1994-12-27 | 1996-07-09 | Kao Corp | 細胞接着抑制剤 |
| CN1070372C (zh) * | 1995-02-15 | 2001-09-05 | 赵国强 | 强力抗癌膏及其制造方法 |
| WO1997015575A1 (en) | 1995-10-27 | 1997-05-01 | Procyon Pharmaceuticals, Inc. | Protein kinase c modulators. y. |
| CN1058620C (zh) | 1995-11-12 | 2000-11-22 | 卢颖 | 一种治疗癌症的外用中成药及配备生产工艺 |
| JPH08268961A (ja) * | 1996-02-28 | 1996-10-15 | Procyon Pharmaceut Inc | 抗炎症組成物 |
| US5932613A (en) * | 1996-07-03 | 1999-08-03 | Millennium Pharmaceuticals, Inc. | Anticancer agents |
| AUPO864097A0 (en) | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
| JP2001139468A (ja) * | 1999-11-11 | 2001-05-22 | Lead Chemical Co Ltd | 抗ウイルス作用を有するホルボール誘導体 |
| US6444555B2 (en) * | 1999-12-07 | 2002-09-03 | Advanced Micro Devices, Inc. | Method for establishing ultra-thin gate insulator using anneal in ammonia |
| AUPQ801700A0 (en) * | 2000-06-07 | 2000-06-29 | Peplin Research Pty Ltd | Enzyme and viral activation |
| AUPQ923100A0 (en) * | 2000-08-07 | 2000-08-31 | Peplin Research Pty Ltd | Treatment of prostate cancer |
| US20030185168A1 (en) * | 2002-03-28 | 2003-10-02 | Yu-Wei Tung | Topology of frequency converting blocks of wireless lan access point |
-
1997
- 1997-08-19 AU AUPO8640A patent/AUPO864097A0/en not_active Abandoned
-
1998
- 1998-08-19 ES ES98938534T patent/ES2308810T3/es not_active Expired - Lifetime
- 1998-08-19 AT AT98938534T patent/ATE397580T1/de active
- 1998-08-19 WO PCT/AU1998/000656 patent/WO1999008994A1/en not_active Ceased
- 1998-08-19 CA CA002301082A patent/CA2301082C/en not_active Expired - Lifetime
- 1998-08-19 PT PT98938534T patent/PT1015413E/pt unknown
- 1998-08-19 DE DE69839586T patent/DE69839586D1/de not_active Expired - Lifetime
- 1998-08-19 CN CN98807751.5A patent/CN1266421B/zh not_active Expired - Lifetime
- 1998-08-19 HU HU0004262A patent/HU228862B1/hu active Protection Beyond IP Right Term
- 1998-08-19 JP JP2000509681A patent/JP2001515059A/ja not_active Withdrawn
- 1998-08-19 US US09/486,199 patent/US6432452B1/en not_active Expired - Lifetime
- 1998-08-19 BR BR9811327-5A patent/BR9811327A/pt not_active Application Discontinuation
- 1998-08-19 DK DK98938534T patent/DK1015413T3/da active
- 1998-08-19 EP EP98938534A patent/EP1015413B1/en not_active Expired - Lifetime
-
2001
- 2001-06-21 US US09/888,997 patent/US6844013B2/en not_active Expired - Lifetime
- 2001-06-21 US US09/888,178 patent/US6787161B2/en not_active Expired - Lifetime
-
2004
- 2004-07-22 US US10/896,811 patent/US7410656B2/en not_active Expired - Lifetime
-
2008
- 2008-08-29 CY CY20081100929T patent/CY1108303T1/el unknown
-
2011
- 2011-11-14 JP JP2011249091A patent/JP2012031212A/ja active Pending
-
2013
- 2013-04-23 BE BE2013C026C patent/BE2013C026I2/fr unknown
- 2013-04-23 LU LU92185C patent/LU92185I2/xx unknown
- 2013-05-13 CY CY2013020C patent/CY2013020I1/el unknown
- 2013-10-30 HU HUS1300063 patent/HUS1300063I1/hu unknown
-
2014
- 2014-10-09 JP JP2014207764A patent/JP2015007130A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HU228862B1 (en) | The use of an ingenane compound for production medicament useful for treatment cancer | |
| KR101128953B1 (ko) | 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 암의 예방 또는 치료용 조성물 | |
| US10966911B2 (en) | Melanin decomposition inhibitor | |
| TWI300352B (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
| KR20150050712A (ko) | 갈색거저리 추출물 또는 이의 분획물을 유효성분으로 포함하는 항암용 조성물 | |
| JP5517946B2 (ja) | 抗新生物活性を有するナンキョクコメススキ（ＤｅｓｃｈａｍｐｓｉａａｎｔａｒｃｔｉｃａＤｅｓｖ．）の新規抽出物 | |
| US20100009017A1 (en) | Anticancer Methods Using Extracts of Anemarrhena asphodeloides Bunge | |
| KR101765141B1 (ko) | 스컬캅플라본 유도체 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물 | |
| KR101673988B1 (ko) | 피부암의 치료 또는 전이 억제용 조성물 | |
| KR101824497B1 (ko) | 피토에스트로겐을 유효성분으로 포함하는 탈모방지 및 모발 성장 촉진용 조성물 | |
| KR20230007796A (ko) | 노화 관련 질환의 예방 또는 치료용 약학 조성물 | |
| WO2007007993A1 (en) | Pharmaceutical composition for the prevention and treatment of liver disease comprising a lonicera caerulea l. var. edulis extract | |
| CN100546593C (zh) | 一种从野山参中制备有抗癌活性的纯化提取物的方法及含有其的组合物 | |
| KR101820085B1 (ko) | 등나무 줄기 추출물, 또는 그의 분획물을 유효 성분으로서 포함하는 미백용 조성물 및 그의 용도 | |
| CA2721087A1 (en) | Anticancer methods using extracts of anemarrhena asphodeloides bunge | |
| KR100602924B1 (ko) | 대추나무주홍하늘소 유충의 똥을 유효성분으로 하는 피부외용약 | |
| KR102113140B1 (ko) | 단삼 및 도인 추출물을 유효성분으로 함유하는 암 예방 또는 치료용 조성물 | |
| KR101852583B1 (ko) | 현사시나무 추출물을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물 | |
| TW202200179A (zh) | 磷酸二酯酶5活性抑制或勃起功能改善用組成物 | |
| KR20130067037A (ko) | 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 암의 예방 또는 치료용 조성물 | |
| KR102769217B1 (ko) | Dld 발현 조절용 조성물 및 이의 용도 | |
| KR102475985B1 (ko) | 대황, 황금 및 황련의 복합 추출물을 유효성분으로 포함하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
| TWI483742B (zh) | 利用含有牡丹皮萃取物之組成物於體外處理細胞之方法及其應用 | |
| KR102633837B1 (ko) | 류마티스 관절염의 개선 및 치료 효능이 우수한 황금 추출물 및 황련 추출물의 혼합물 제조방법 및 상기 혼합물을 포함하는 류마티스 관절염의 예방 또는 치료용 조성물 | |
| JP2020186215A (ja) | 更年期症状改善用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB9A | Succession in title |
Owner name: LEO LABORATORIES LIMITED, IE Free format text: FORMER OWNER(S): PEPLIN BIOTECH PTY. LTD., AU; PEPLIN RESEARCH PTY LTD, AU |
|
| AA1S | Information on application for a supplementary protection certificate |
Free format text: PRODUCT NAME: INGENANE OR A DERIVATIVE (SALT OR ESTER THEREOF); REG. NO/DATE: EU/1/12/796/001-002 20121115 Spc suppl protection certif: S1300063 Filing date: 20131030 Expiry date: 20180819 |
|
| FG4S | Grant of supplementary protection certificate |
Spc suppl protection certif: S1300063 Filing date: 20131030 Expiry date: 20180819 Extension date: 20230819 |